research Aldo-Keto Reductase (AKR) 1C3 Inhibitors: A Patent Review 70 citations, September 2017 in “Expert opinion on therapeutic patents” The review suggests that while many AKR1C3 inhibitors show promise for treating certain cancers, more research is needed to confirm their effectiveness in humans.